ALT

Business Context and Reporting Period

This summary covers the Form 10-Q filed by PharmAthene, Inc. (Note: The input metadata referenced "Altimmune," but the filing text explicitly identifies the registrant as PharmAthene, Inc.) for the quarterly period ended June 30, 2010. PharmAthene is a biopharmaceutical company focused on developing biodefense countermeasures, including vaccines and therapeutics for anthrax (SparVax, Valortim) and nerve agents (Protexia). The company operates primarily under cost-plus-fee contracts and grants from U.S. government agencies such as the Department of Defense (DoD), BARDA, and NIAID.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue for the three months ended June 30, 2010, decreased to $4.78 million from $8.07 million in the prior year period. The six-month revenue dropped to $7.90 million from $13.59 million. This decline is primarily attributed to the completion of the first phase of the Protexia contract in late 2009 and the absence of one-time settlement revenue recognized in 2009 related to the Avecia acquisition.
• Expense Reduction: Research and Development (R&D) expenses decreased significantly to $5.94 million (Q3) and $10.89 million (YTD) compared to $10.23 million and $16.04 million in the prior year periods. This reduction was driven by the wind-down of the RypVax plague vaccine program and the absence of a $3.0 million one-time termination fee paid to Avecia in 2009.
• Liquidity Deterioration: Cash and cash equivalents dropped from $2.67 million at year-end 2009 to $0.68 million at June 30, 2010. This was caused by operating cash outflows and delays in billing/collections related to the SparVax program, exacerbated by a third-party bid protest that resulted in a temporary "stop-work" order.
• Equity Deficit: The company moved from a positive stockholders' equity of $1.88 million at December 31, 2009, to a deficit of $(9.60) million at June 30, 2010, due to accumulated net losses.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: Management stated that based on current operating requirements and expected government receipts, they do not anticipate requiring additional funding to continue operations through the end of 2010. However, they may elect to raise capital to expand the business or if cost estimates prove incorrect.
• Recent Financing: In April 2010, the company raised approximately $2.5 million in gross proceeds. In July 2010 (subsequent to the period end), the company completed a public sale raising approximately $3.9 million in gross proceeds.
• Listing Compliance Risk: In July 2010, the NYSE Amex notified the company of non-compliance with continued listing standards due to stockholders' equity falling below $2.0 million and recurring net losses. The company must submit a plan to regain compliance by January 26, 2012, or face delisting.
• Legal Contingencies:
  • SIGA Litigation: Ongoing litigation with Siga Technologies regarding rights to the drug candidate ST-246. Trial is scheduled to commence January 3, 2011. No accrual has been made as an unfavorable outcome is not deemed probable.
  • Avecia Payment Obligation: The company may be required to pay Avecia $5 million if a specific multi-year funded development contract (RFP-BARDA-08-15 or a substitute) is entered into. The original RFP was cancelled in December 2009.
• Government Contract Risks: Revenue is heavily dependent on U.S. government contracts. Delays in funding decisions for Protexia and SparVax, as well as potential budget cuts, pose significant risks. A bid protest regarding the SparVax contract caused work stoppages and billing delays in the first half of 2010.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $0.68 million cash balance plus the $3.9 million raised in July 2010 to fund operations through 2010, given the high burn rate and potential for further delays in government payments.
• Delisting Status: Monitor the acceptance and progress of the compliance plan submitted to the NYSE Amex to avoid delisting, which could severely impact stock liquidity.
• Government Funding Decisions: Track the DoD's decision on the next phase of funding for the Protexia program and the status of the SparVax contract following the resolution of the bid protest.
• Debt Maturity: Note the maturity of $19.3 million in convertible notes on July 28, 2011, and the company's ability to refinance or convert this debt.
• Valortim Clinical Hold: Monitor the FDA's resolution of the partial clinical hold on the Valortim trial, which is a prerequisite for further BARDA funding negotiations.